Dabrafenib

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
November 2014
 

Comments

RED:

  • NICE TA321: for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.  (Decision date - November 2014).
  • NICE TA544: with trametinib for adjuvant treatment of resected BRAF V600 mutation positive melanoma.  (Decision date - Nov 2018).
  • NHSE SSC2444: Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer.  NHSE commissioned.  (Decision date - November 2022).
  • NICE TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. (Decision date - July 2023)

DO NOT PRESCRIBE (DNP):

  • NICE TA564: with trametinib for treating advanced metastatic BRAF V600E mutation-positive NSCLC.  (Terminated appraisal).  (Decision date - March 2019).

Black Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again